Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
about
Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectivesClinical roles of the aberrantly expressed lncRNAs in lung squamous cell carcinoma: a study based on RNA-sequencing and microarray data mining.PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.Maintenance treatment with gemcitabine have a promising activity on metastatic bladder cancer survivalPD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients.PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed.Trial watch: Immune checkpoint blockers for cancer therapy.Immune checkpoint inhibitors in advanced non-small cell lung cancer.Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy.PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody.Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule.Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens.PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model.The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysisNivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safetyAssociation of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab
P2860
Q33884361-402E3C78-E031-4665-9A75-67E7989B43EDQ36395226-024FA3DE-74EB-4784-A801-D1CE851DC1F2Q38607549-33599790-8744-47F8-848E-A6BA6C656337Q38670099-F51F49D2-2DB2-43BB-A9AB-E4EB1E7DB0A0Q38687631-A2B3096F-31B9-481C-AF2B-AEAD2B0DD92BQ41455651-6218A4C0-4080-433C-B632-D3EB9DBE9F70Q42354900-F84F9706-9D9C-477A-B98E-E6D449348B6EQ42371630-101FDDD5-35B8-4CA7-9A33-965C9C971725Q47393365-23C32FF6-0968-49D9-9F64-FA65E9CFF2B5Q47563451-0042D9CD-17CB-4114-B1E7-661E54521037Q47734616-82F52999-7D3B-4465-9FEA-BC4EFC80D2C8Q50445792-D20C0564-74CC-4A15-A857-A2CD02274589Q55132758-D0C6DBED-0695-468B-B9B2-CF663BFB34B3Q55262681-B7EBDF33-FE2B-4FBC-9DDF-5D8B11585B86Q55378703-5C96D73A-7A9D-4EEA-AEF9-9D7A81CCB127Q58698737-F4482A65-3669-4F4B-86CC-C9C55DFB592DQ58699010-16F14C83-CFD5-47E5-BBD2-069E013B0CC7Q58738102-EA4819D2-D968-4C94-B639-3AF538781D6E
P2860
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety and efficacy of nivolum ...... r: a four arms phase Ib study.
@en
Safety and efficacy of nivolum ...... r: a four arms phase Ib study.
@nl
type
label
Safety and efficacy of nivolum ...... r: a four arms phase Ib study.
@en
Safety and efficacy of nivolum ...... r: a four arms phase Ib study.
@nl
prefLabel
Safety and efficacy of nivolum ...... r: a four arms phase Ib study.
@en
Safety and efficacy of nivolum ...... r: a four arms phase Ib study.
@nl
P2093
P2860
P356
P1433
P1476
Safety and efficacy of nivolum ...... er: a four arms phase Ib study
@en
P2093
H Horinouchi
H Mizugaki
H Nokihara
H Shiraishi
P2860
P304
P356
10.1093/ANNONC/MDW416
P577
2016-10-20T00:00:00Z